Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient.
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major cause of infection in both the hospital and community setting. Obesity is a risk factor for infection, and the prevalence of this disease has reached epidemic proportions worldwide. Treatment of infections in this special population is a challenge given the lack of data on the optimal antibiotic choice and dosing strategies, particularly for treatment of MRSA infections. Obesity is associated with various physiological changes that may lead to altered pharmacokinetic parameters. These changes include altered drug biodistribution, elimination, and absorption. This review provides clinicians with a summary of the literature pertaining to the pharmacokinetic and pharmacodynamic considerations when selecting antibiotic therapy for the treatment of MRSA infections in obese patients.
['Narayanan|Navaneeth|N|', 'Adams|Christopher D|CD|', 'Kubiak|David W|DW|', 'Cheng|Serena|S|', 'Stoianovici|Robyn|R|', 'Kagan|Leonid|L|', 'Brunetti|Luigi|L|']
methicillin-resistant Staphylococcus aureus obesity antibiotics pharmacokinetics